KMT2A and acute myeloid leukemia: The Phase I data of SNDX-5613 from AUGMENT-101 (NCT04065399) were presented at the 2021 ASH Annual Meeting [42], and SNDX-5613 exhibited promising efficacy in the MLL1-r AML/ALL and NPM1c AML.